JP2005536522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005536522A5 JP2005536522A5 JP2004523742A JP2004523742A JP2005536522A5 JP 2005536522 A5 JP2005536522 A5 JP 2005536522A5 JP 2004523742 A JP2004523742 A JP 2004523742A JP 2004523742 A JP2004523742 A JP 2004523742A JP 2005536522 A5 JP2005536522 A5 JP 2005536522A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound according
- phenyl
- pharmaceutically acceptable
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 11
- 206010013663 drug dependence Diseases 0.000 claims description 10
- 230000036407 pain Effects 0.000 claims description 8
- 208000011117 substance-related disease Diseases 0.000 claims description 7
- 208000007914 Labor Pain Diseases 0.000 claims description 6
- 208000035945 Labour pain Diseases 0.000 claims description 6
- 208000007848 Alcoholism Diseases 0.000 claims description 5
- 201000007930 alcohol dependence Diseases 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 201000006145 cocaine dependence Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000012488 Opiate Overdose Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 230000000391 smoking effect Effects 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 description 5
- 102000003840 Opioid Receptors Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 102000051367 mu Opioid Receptors Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 108020001612 μ-opioid receptors Proteins 0.000 description 3
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 2
- 108700023159 delta Opioid Receptors Proteins 0.000 description 2
- 102000048124 delta Opioid Receptors Human genes 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000018526 Narcotic-Related disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201143 | 2002-07-26 | ||
| PCT/DK2003/000510 WO2004011468A1 (en) | 2002-07-26 | 2003-07-24 | Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005536522A JP2005536522A (ja) | 2005-12-02 |
| JP2005536522A5 true JP2005536522A5 (https=) | 2010-05-20 |
| JP4588444B2 JP4588444B2 (ja) | 2010-12-01 |
Family
ID=30775758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004523742A Expired - Fee Related JP4588444B2 (ja) | 2002-07-26 | 2003-07-24 | ジアザビシクロノナン及び−デカン誘導体並びにこれをオピオイドレセプターリガンドとして使用する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7358243B2 (https=) |
| EP (1) | EP1527075B1 (https=) |
| JP (1) | JP4588444B2 (https=) |
| CN (1) | CN100340561C (https=) |
| AT (1) | ATE390427T1 (https=) |
| AU (1) | AU2003280306B2 (https=) |
| CA (1) | CA2489165A1 (https=) |
| DE (1) | DE60319989T2 (https=) |
| MX (1) | MXPA05001002A (https=) |
| NZ (1) | NZ537182A (https=) |
| WO (1) | WO2004011468A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040954A1 (it) * | 2004-05-12 | 2004-08-12 | Univ Degli Studi Milano | Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica |
| IT1395452B1 (it) * | 2009-02-25 | 2012-09-21 | Neuroscienze Pharmaness S C A Rl | Microemulsioni |
| IT1390848B1 (it) | 2008-07-31 | 2011-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
| EP2149370A1 (en) * | 2008-07-31 | 2010-02-03 | Neuroscienze Pharmaness S.C. A R.L. | Diazabicyclic compounds and microemulsions thereof |
| IT1390850B1 (it) * | 2008-07-31 | 2011-10-19 | Neuroscienze Pharmaness S C A R L | Microemulsioni |
| IT1394400B1 (it) | 2009-02-25 | 2012-06-15 | Neuroscienze Pharmaness S C Ar L | Composizioni farmaceutiche |
| IT1396951B1 (it) | 2009-12-18 | 2012-12-20 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
| EP2789619A1 (en) | 2013-04-12 | 2014-10-15 | Kemotech S.r.l. | Pharmaceutical compounds wiht angiogenesis inbhibitory activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1274018B (it) * | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
| NZ513575A (en) * | 1999-05-04 | 2003-07-25 | Neurosearch As | Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators |
| IT1317841B1 (it) * | 2000-02-18 | 2003-07-15 | Univ Degli Studi Milano | Derivati del 3,9-diazabiciclo(3.3.1)nonano ad attivita' analgesica. |
| WO2001072303A1 (en) | 2000-03-29 | 2001-10-04 | Research Triangle Institute | Selective ligands for the delta opioid receptor |
-
2003
- 2003-07-24 NZ NZ537182A patent/NZ537182A/en not_active IP Right Cessation
- 2003-07-24 AU AU2003280306A patent/AU2003280306B2/en not_active Ceased
- 2003-07-24 MX MXPA05001002A patent/MXPA05001002A/es active IP Right Grant
- 2003-07-24 AT AT03771053T patent/ATE390427T1/de not_active IP Right Cessation
- 2003-07-24 WO PCT/DK2003/000510 patent/WO2004011468A1/en not_active Ceased
- 2003-07-24 CA CA002489165A patent/CA2489165A1/en not_active Abandoned
- 2003-07-24 DE DE60319989T patent/DE60319989T2/de not_active Expired - Lifetime
- 2003-07-24 EP EP03771053A patent/EP1527075B1/en not_active Expired - Lifetime
- 2003-07-24 CN CNB038172828A patent/CN100340561C/zh not_active Expired - Fee Related
- 2003-07-24 JP JP2004523742A patent/JP4588444B2/ja not_active Expired - Fee Related
- 2003-07-24 US US10/521,559 patent/US7358243B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10682354B2 (en) | Compositions and methods | |
| JP2012526736A5 (https=) | ||
| CA2744736C (en) | Compositions comprising nicotinic agonists and methods of using same | |
| US6716854B2 (en) | Treatments for restless legs syndrome | |
| JP2010535801A5 (https=) | ||
| JP2020528430A5 (https=) | ||
| CN1468111A (zh) | 治疗急性、慢性疼痛和/或神经病性疼痛和偏头痛的药物组合物 | |
| US7164021B2 (en) | Opiate analogs selective for the δ-opioid receptor | |
| AU4185496A (en) | Use of a tachykinin antagonist and an opioid analgesic | |
| JP2003509371A (ja) | ５−ヒドロキシトリプタミン・レセプタ／α２アドレナリン作用性レセプタ拮抗薬組成物の投与による運動障害の処置 | |
| JPH08509238A (ja) | Ｇａｂａアゴニストの新規医学的用途 | |
| JP2006503850A5 (https=) | ||
| JP2005536522A5 (https=) | ||
| JPS6342605B2 (https=) | ||
| HU219907B (hu) | Eljárás morfinfüggőség elkerülésére szolgáló, flupirtint és morfint tartalmazó gyógyszerkészítmények előállítására | |
| CN1527711A (zh) | 用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物 | |
| WO2001034125A2 (en) | Therapeutic use and formulation of (-)-tramadol | |
| MX2008015887A (es) | Tratamiento de condiciones psicologicas utilizando antagonista m1 de receptor muscarinico. | |
| CN101437516B (zh) | 使用纳美芬及其类似物治疗疾病 | |
| JPH05132430A (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| JP2014505113A (ja) | 末梢作用性μオピオイドアンタゴニスト | |
| EP2846806B1 (en) | Treatment of respiratory depression | |
| JP2007528892A (ja) | 認知機能の減退を阻止するための複合医薬組成物 | |
| JP2004509869A5 (https=) | ||
| AU2005237538B2 (en) | Methods of diminishing co-abuse potential |